Sangamo Therapeutics Announces Second Quarter 2025 Earnings Call
Rhea-AI Summary
Sangamo Therapeutics (Nasdaq: SGMO), a genomic medicine company, has scheduled its second quarter 2025 financial results release for Thursday, August 7, 2025, after market close. The company will host a conference call at 4:30 p.m. Eastern the same day to discuss financial results and provide business updates.
Participants can register and access the call through a provided link, with a recommended join time of 10 minutes before the event. The webcast will be available in the Investors and Media section of Sangamo's website, with a replay accessible after the call.
[]Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, SGMO gained 4.56%, reflecting a moderate positive market reaction. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $6M to the company's valuation, bringing the market cap to $140M at that time.
Data tracked by StockTitan Argus on the day of publication.
RICHMOND, Calif., July 31, 2025 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company today announced that the company has scheduled the release of its second quarter 2025 financial results after the markets close on Thursday, August 7, 2025.
The company will hold a conference call at 4:30 p.m. Eastern on Thursday, August 7, which will remain open to the public. During the conference call, the company will review its financial results and provide business updates.
Participants should register for, and access, the call using this link. While not required, it is recommended to join 10 minutes prior to the event start. Once registered, participants will be given the option to either dial into the call with the number and unique passcode provided, or to use the dial-out option to connect their phone instantly. The link to access the live webcast can also be found on the Sangamo Therapeutics website in the Investors and Media section under Events.
A replay will be available following the conference call, accessible under Events.
About Sangamo Therapeutics
Sangamo Therapeutics is a genomic medicine company dedicated to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases who do not have adequate or any treatment options. Sangamo believes that its zinc finger epigenetic regulators are ideally suited to potentially address devastating neurological disorders and that its capsid discovery platform can expand delivery beyond currently available intrathecal delivery capsids, including in the central nervous system. Sangamo’s pipeline also includes multiple partnered programs and programs with opportunities for partnership and investment. To learn more, visit www.sangamo.com and connect with us on LinkedIn and X.
Investor Relations
Louise Wilkie
ir@sangamo.com
Media Inquiries
Melinda Hutcheon
media@sangamo.com
FAQ
When will Sangamo Therapeutics (SGMO) release Q2 2025 earnings?
How can investors access Sangamo's Q2 2025 earnings call?
Will there be a replay available of Sangamo's Q2 2025 earnings call?
What time should participants join Sangamo's Q2 2025 earnings call?
